The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

Johnson & Johnson has reported Phase III data where CARVYKTI improved overall survival in patients with multiple myeloma.

The trial enrolled chronic myeloid leukaemia patients irrespective of their T315I mutation status. Credit: Nemes Laszlo/Shutterstock. Enliven Therapeutics has reported the latest positive results from ...

This week on Pipeline Moves, we kick off by looking at Pfizer’s topline data from a Phase II trial of ponsegromab on cancer cachexia. Meanwhile, IMPACT Therapeutics senaparib has seen its phase ...